Home › Funds › Madison Avenue Partners, LP › INDV

Madison Avenue Partners, LP position in INDV

INDIVIOR PHARMACEUTICALS INC · Health Care

Madison Avenue Partners, LP reported holding 2,874,368 shares of INDV (INDIVIOR PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$117.9M, representing 5.08% of its reported portfolio and ranking #9 among its reported holdings. Madison Avenue Partners, LP has disclosed INDV holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.87M sh
Reported value held$117.94M
Portfolio Weight5.08%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Madison Avenue Partners, LP's INDV position evolved

Madison Avenue Partners, LP first disclosed a stake in INDV in Q3 2023 at 39,087 shares (US$902K). The position peaked in Q4 2025 at 6,280,502 shares, worth US$225.3M. Across 12 filings, Madison Avenue Partners, LP increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,874,368 shares valued at US$117.9M — a reduction of -1,440,794 shares quarter over quarter.. Notable position changes include a 125% increase in Q1 2024, a 1673% increase in Q3 2024, a 112% increase in Q1 2025 (shares rose 55% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 39.09K $901.74K New
Q4 2023 72.25K $1.10M Add
Q1 2024 162.90K $3.49M Add
Q2 2024 223.43K $3.60M Add
Q3 2024 3.96M $38.62M Add
Q4 2024 3.67M $45.66M Reduce
Q1 2025 7.79M $74.26M Add
Q2 2025 7.92M $116.77M Add
Q3 2025 6.46M $155.84M Reduce
Q4 2025 6.28M $225.34M Reduce
Q1 2026 4.32M $131.53M Reduce
Q2 2026 2.87M $117.94M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About INDV and 13F data

INDV (INDIVIOR PHARMACEUTICALS INC) is a Health Care company. 53 other funds we track also report a position in INDV — the largest reported positions include OAKTREE CAPITAL MANAGEMENT LP (US$251.4M), Two Seas Capital LP (US$131.6M), MANGROVE PARTNERS IM, LLC (US$109.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding INDV

All INDV fund holders →

FAQ

How long has Madison Avenue Partners, LP held INDV?

Madison Avenue Partners, LP has disclosed INDV holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Madison Avenue Partners, LP's current position in INDV?

As of Q2 2026, Madison Avenue Partners, LP holds 2.87M shares of INDV (INDIVIOR PHARMACEUTICALS INC), valued at $117.94M, representing 5.08% of its reported portfolio and ranking #9.

Has Madison Avenue Partners, LP been buying or selling INDV?

In the latest 13F filing (Q2 2026), Madison Avenue Partners, LP reduced its position in INDV. The position peaked in Q4 2025 at 6.28M shares.

Which other funds hold INDV?

Other major institutional holders of INDV include OAKTREE CAPITAL MANAGEMENT LP, Two Seas Capital LP, MANGROVE PARTNERS IM, LLC, among 53 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.